Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study (vol 41, pg 3523, 2023)

被引：0

作者：

Cartron

机构：

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 25期

关键词：

D O I：

10.1200/JCO.23.01377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4187 / 4187

页数：1

共 50 条

[21] Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Penalver, Francisco-Javier
Marquez, Jose-Antonio
Duran, Soledad
Giraldo, Pilar
Martin, Alejandro
Montalban, Carlos
Sancho, Juan-Manuel
Ramirez, Maria-Jose
Terol, Maria-Jose
Capote, Francisco-Javier
Gutierrez, Antonio
Sanchez, Blanca
Lopez, Andres
Salar, Antonio
Rodriguez-Caravaca, Gil
Canales, Miguel
Caballero, Maria-Dolores
Bello Lopez, Jose Luis
Carbonell, Felix
Ferrer Bordas, Secundino
Font Lopez, Patricia
Perez Persona, Ernesto
Lopez Guillermo, Armando
Hernandez Martin, Roberto
Ramon Mayans, Jose
Palomera, Luis
Perez Ceballos, Elena
Queizan Hernandez, Jose Antonio
Riaza Grau, Rosalia
de la Cruz, Fatima
Sanchez Salinas, Andres
CANCER MEDICINE, 2019, 8 (16): : 6955 - 6966
[22] Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas - First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)
Rummel, Mathias J.
Von Gruenhagen, U.
Niederle, N.
Rothmann, F.
Ballo, H.
Weidmann, E.
Welslau, M.
Heil, G.
Duerk, H.
Stauch, M.
Losem, C.
Matzdorff, A.
Balser, C.
Schalk, K.
Kofahl-Krause, D.
Kaiser, U.
Knauf, W.
Banat, A.
Hoelzer, D.
Brugger, W.
BLOOD, 2007, 110 (11) : 120A - 120A
[23] Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL).
Rummel, Mathias J.
von Gruenhagen, Ulrich
Niederle, Norbert
Ballo, Harald
Weidmann, Eckhart
Welslau, Manfred
Heil, Gerhard
Balser, Christina
Duerk, Heinz A.
Stauch, Martina
Kofahl-Krause, Dorothea
Kaiser, Ulrich
Knauf, Wolfgang
Brugger, Wolfram
BLOOD, 2008, 112 (11) : 900 - 900
[24] Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
Cottereau, Anne Segolene
Rebaud, Louis
Trotman, Judith
Feugier, Pierre
Nastoupil, Loretta J.
Bachy, Emmanuel
Flinn, Ian W.
Haioun, Corinne
Ysebaert, Loic
Bartlett, Nancy L.
Tilly, Herve
Casasnovas, Rene-Olivier
Ricci, Romain
Portugues, Cedric
Buvat, Irene
Meignan, Michel
Morschhauser, Franck
BLOOD, 2022, 140 : 6474 - 6476
[25] Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi
Vitolo, Umberto
Ladetto, Marco
Boccomini, Carola
Baldini, Luca
De Angelis, Federico
Tucci, Alessandra
Botto, Barbara
Chiappella, Annalisa
Chiarenza, Annalisa
Pinto, Antonello
De Renzo, Amalia
Zaja, Francesco
Castellino, Claudia
Bari, Alessia
De Celis, Isabel Alvarez
Evangelista, Andrea
Parvis, Guido
Gamba, Enrica
Lobetti-Bodoni, Chiara
Ciccone, Giovannino
Rossi, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) : 3351 - +
[26] Bendamustine plus rituximab versus chop plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas-interim results of a randomized phase III study of the stil (study group indolent lymphomas, germany)
Rummel, M. J.
ANNALS OF ONCOLOGY, 2008, 19 : 173 - 173
[27] Rituximab in combination with CHOP results in a significantly superior response rate and time to treatment failure in first-line treatment of lymphomplasmocytoid/ic immunocytoma (LP-IC) - A prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
Buske, C
Dreyling, M
Eimermacher, H
Boeck, H
Pfreundschuh, M
Metzner, B
Unterhalt, M
Hiddemann, W
ANNALS OF ONCOLOGY, 2005, 16 : 110 - 110
[28] Addition of rituximab to first-line MCP (mitoxantrone, chlorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma - 4 year follow-up results of a phase III trial of the east German study group hematology and oncology (OSHO#39).
Herold, Michael
Haas, Antje
Srock, Stephanie
Neser, Sabine
Al Ali, Kathrin H.
Neubauer, Andreas
Doelken, Gottfried
Naumann, Ralph
Fietz, Thomas
Freund, Mathias
Rohrberg, Robert
Hoeffken, Klaus
Franke, Astrid
Ittel, Thomas H.
Kettner, Erika
BLOOD, 2006, 108 (11) : 147A - 147A
[29] Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)
Rummel, Mathias
Buske, Christian
Hertenstein, Bernd
Lerchenmueller, Christian
Koenigsmann, Michael
Lange, Elisabeth
Reeb, Manfred
Kaiser, Ulrich
Balser, Christina
Behringer, Dirk
Duerig, Jan
Gaska, Tobias
Maschmeyer, Georg
Schliesser, Georg
Burchardt, Alexander C.
Barth, Juergen
Kauff, Frank
Hinke, Axel
Greil, Richard
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S101 - S103
[30] Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).
Rummel, Mathias J.
Knauf, Wolfgang
Goerner, Martin
Soeling, Ulrike
Lange, Elisabeth
Hertenstein, Bernd
Eggert, Jochen
Schliesser, Georg C.
Weide, Rudolf
Blumenstengel, Klaus
Detlefsen, Ninia
Hinke, Axel
Kauff, Frank
Barth, Juergen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →